Response to Treatment Series: Part 1 and introduction, measuring tumor response - Challenges in the era of molecular medicine

American Journal of Roentgenology

Volumn 197, Issue 1, 2011, Pages 15-17

  Sullivan, Daniel C ^a   Gatsonis, Constantine ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Cancer; Molecular medicine; Tumor response

Indexed keywords

BIOLOGICAL MARKER; CYTOTOXIC AGENT;

CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RECURRENCE; CLINICAL TRIAL (TOPIC); CRITERION VARIABLE; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG TARGETING; GENE MUTATION; GROWTH INHIBITION; MOLECULAR IMAGING; NOTE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; SCINTIGRAPHY; SOLID TUMOR; STANDARD; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR RESPONSE; TUMOR VOLUME; WORLD HEALTH ORGANIZATION;

HUMANS; MOLECULAR IMAGING; MOLECULAR PROBE TECHNIQUES; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 79960481685     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.7083     Document Type: Note

References (16)

1. Mukherjee S. The emperor of all maladies: a biography of cancer. New York, NY: Scribner, 2010
2. Dictionary.com Website. The American Heritage Stedman's medical dictionary. dictionary.reference. com/browse/response. Accessed January 31, 2011
3. World Health Organization. WHO handbook of reporting results of cancer treatment. Geneva, Switzerland: World Health Organization, 1979
4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
5. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247
6. Yaghmai V, Miller FH, Rezai P, Benson AB III, Salem R. Tumor response assessment: using new and conventional criteria. AJR 2011; 197:18-27
7. Lebwohl D, Kay A, Berg W, Baladi JF, Zheng J. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. Cancer J 2009; 15:386-394
8. Vidaurre T, Wilkerson J, Simon R, Bates SE, Fojo T. Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development. Cancer J 2009; 15:366-373
9. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458:719-724
10. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70 (Pubitemid 30046295)
11. Kalbfleisch J, Prentice R. The statistical analysis of failure time data, 2nd ed. New York, NY: Wiley, 2002
12. Lindsey JC, Ryan LM. Methods for interval-censored data. Stat Med 1998; 17:219-238
13. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000; 56:337-344 (Pubitemid 30422619)
14. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics 2005; 61:92-105 (Pubitemid 40380968)
15. Sargent DJ, Rubinstein L, Schwartz L, et al. Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer 2009; 45:290-299
16. Korn EL, Albert PS, McShane LM. Assessing surrogates as trial endpoints using mixed models. Stat Med 2005; 24:163-182 (Pubitemid 40124164)